程颖教授领衔：近60%缓解，重磅ADC治疗中国肺癌患者数据揭晓 | AACR
医学新视点约 6 分钟本次AACR年会上，还有哪些研究成果为肿瘤诊治难题带来全新曙光？我们为您盘点了入选突破性研究（Late-Breaking Research）的重要进展和中国创新疗法，长按或扫描下方二维码，即可获取。
客观缓解率（ORR）：经ICR（独立中心审查委员会）评估为58.3%（95% CI 46.1%~69.8%），这也是研究的主要结局；经INV（研究者）评估数据一致（次要结局之一）。 中位缓解持续时间（DOR）：经ICR评估尚未达到，经INV评估为9.0个月。 疾病控制率（DCR）：经ICR评估为91.7%，经INV评估为93.1%。 中位无进展生存期（PFS）：经ICR评估尚未达到，经INV评估为10.8个月。 1年进展生存生存率：经ICR评估为55.1%，和INV评估为39.7%。
我们为您盘点了本次AACR年会中入选突破性研究（Late-Breaking Research）的重要进展和中国创新疗法，长按或扫描下方二维码，即可获取。
欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。
题图来源：123RF
参考资料（可上下滑动查看）
[1] CT248 / 7 - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Retrieved April 8, 2024 from https://www.abstractsonline.com/pp8/#!/20272/presentation/11569
[2] A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC (DL-05). Retrieved April 8, 2024 fromhttps://classic.clinicaltrials.gov/ct2/show/NCT05246514
[3] Antonio Passaro, Solange Peters. (2022). Targeting HER2-Mutant NSCLC — The Light Is On. The N Engl J Med, DOI: 10.1056/NEJMe2119442
[4] Li, X., Zhao, C., Su, C. et al. (2016). Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China. BMC Cancer, DOI: https://doi.org/10.1186/s12885-016-2875-z
[5] Chenguang Li, et al., (2012). A fraction of lung adenocarcinomas harbor activating mutations in the HER2 kinase domain. HER2-targeted therapies have shown minimal benefit in molecularly unselected patients. We investigated clinical and potential molecular factors associated with HER2-mutant lung adenocarcinoma. Journal of Thoracic Oncology, DOI: https://doi.org/10.1097/JTO.0b013e318234f0a2.
[6] M. Riudavets, et al., (2021) .Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open, DOI: https://doi.org/10.1016/j.esmoop.2021.100260
[7] FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. Retrieved April 5, 2024 from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
[8] 重磅 | 优赫得®在华获批作为首个针对HER2低表达转移性乳腺癌的抗HER2靶向疗法. Retrieved April 8, 2024 from https://www.astrazeneca.com.cn/zh/media/press-releases/2023/07-12-01.html
分享，点赞，在看，传递医学新知